The Influence of SSRI’s in Multiple System Atrophy


About this study

  1. To evaluate whether SSRI use is associated with increased survival time and slower disease progression among patients with MSA.

  2. To evaluate whether SSRI use is associated with the presence of clinical respiratory insufficiency such as stridor.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

The medical record database at Mayo Clinic, Rochester will be queried to identify all cases of MSA with identifiers of multiple system atrophy, multiple systems atrophy, multisystem atrophy, MSA, MSA-P, MSA-C, Shy-Drager syndrome, cerebellar ataxia, parkinsonism, or parkinsonian features and autonomic dysfunction on coding or final diagnosis.  

This project does not involve experimentation of human subjects and is limited only to a retrospective review of medical records and available database information. There will be no patient contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Wolfgang Singer, M.D.

Closed-enrolling by invitation

What is this? (?)
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Tonette Gehrking CAP

(507) 284-4462

More information


Publications are currently not available

Mayo Clinic Footer